Disease‐specific survival · Patients with brain metastases
Whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) showed no clear difference in disease‐specific survival compared with WBRT (moderate certainty).
1 finding from 1 review
Local tumor control · Patients with brain metastases
Whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) probably leads to lower local tumor control compared with WBRT (moderate certainty).
1 finding from 1 review
Functionally independent survival (KPS) · Patients with brain metastases
Whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) showed no clear difference in functionally independent survival (KPS) compared with WBRT (moderate certainty).
1 finding from 1 review
Steroid use · Patients with brain metastases
Whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) may leads to lower steroid use compared with WBRT (low certainty).
1 finding from 1 review
Overall survival · people with metastatic CRC
Modern chemotherapy regimens probably leads to lower overall survival compared with 5‐flourouracil (moderate certainty).
1 finding from 1 review
Overall survival · people with metastatic CRC
Irinotecan‐based regimens showed no clear difference in overall survival compared with irinotecan (low certainty).
1 finding from 1 review
Tumour response · people with metastatic CRC
Irinotecan‐based regimens leads to higher overall tumour response compared with irinotecan (high certainty).
1 finding from 1 review
Severe adverse effects · people with metastatic CRC
Irinotecan‐based regimens showed no clear difference in severe adverse effects compared with irinotecan (moderate certainty).
1 finding from 1 review
Overall survival · people with metastatic CRC
Irinotecan + oxaliplatin probably leads to lower overall survival compared with irinotecan (moderate certainty).
1 finding from 1 review
Progression‐free survival · people with metastatic CRC
Irinotecan + oxaliplatin probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).
1 finding from 1 review
Tumour response · people with metastatic CRC
Irinotecan + oxaliplatin probably leads to higher overall tumour response compared with irinotecan (moderate certainty).
1 finding from 1 review
Severe adverse effects · people with metastatic CRC
Irinotecan + oxaliplatin probably leads to higher severe adverse effects compared with irinotecan (moderate certainty).
1 finding from 1 review
Overall survival · people with metastatic CRC
Chemotherapy probably leads to lower overall survival compared with best supportive care (moderate certainty).
1 finding from 1 review
Progression‐free survival · people with metastatic CRC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response · people with metastatic CRC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · people with metastatic CRC
Modern chemotherapy regimens leads to lower progression‐free survival compared with 5‐flourouracil (high certainty).
1 finding from 1 review
Severe adverse effects · people with metastatic CRC
Chemotherapy probably leads to higher severe adverse effects compared with best supportive care (moderate certainty).
1 finding from 1 review
Overall survival · people with metastatic CRC
FOLFIRI + targeted therapy leads to lower overall survival compared with FOLFIRI (high certainty).
1 finding from 1 review
Progression‐free survival · people with metastatic CRC
FOLFIRI + targeted therapy leads to lower progression‐free survival compared with FOLFIRI (high certainty).
1 finding from 1 review
Tumour response · people with metastatic CRC
FOLFIRI + targeted therapy probably leads to higher overall tumour response compared with FOLFIRI (moderate certainty).
1 finding from 1 review